Lilly, Incyte Announce Initial Data From Adaptive
COVID-19 Treatment Trial - Quick Facts
RTTNews - Sep. 14, 2020
(RTTNews) - Eli Lilly and Co. (LLY) and Incyte Corp. (INCY) announced
Monday initial data emerging from the Adaptive COVID-19 Treatment Trial
(ACTT-2) sponsored by the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health (NIH).
ACTT-2 included more than 1,000 patients and began on May 8 to assess
the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus
remdesivir in hospitalized patients with COVID-19. Baricitinib in combination
with remdesivir met the primary endpoint of reduction of time to recovery
in comparison with remdesivir.
An independent data and safety monitoring board overseeing the double-
blind, randomized controlled trial met regularly throughout the trial to review
safety data. Additional analyses are ongoing to understand other clinical
outcome data, including mortality and safety data.
Based on the ACTT-2 data, Lilly plans to discuss the potential for emergency
use authorization (EUA) with the U.S. Food and Drug Administration (FDA)
and to explore similar measures with other regulatory agencies for baricitinib
as a treatment of hospitalized patients with COVID-19. If authorized for use,
Lilly will propose that baricitinib be available through commercial channels
and will work with hospitals and governments to ensure patient access.
In the U.S., baricitinib is approved for RA patients at a 2-mg daily dose; an
EUA would potentially authorize a 4-mg dose for COVID-19.
Baricitinib, a JAK1/JAK2 inhibitor licensed to Lilly from Incyte and marketed
as OLUMIANT, is approved in more than 70 countries as a treatment for
adults with moderately to severely active RA.
Lilly is also currently supporting ongoing multisite and single-site investigator-
initiated trials in Europe and North America for hospitalized patients with
COVID-19 infections.
o~~~ O |
